Cellectar Biosciences, Inc. (CLRB)
NASDAQ (CM) NASDAQ (CM) Primary 
XFRA Summary
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| JG Joseph Gentili Riverview Capital Advisers LLC | 10,384 | $73,830.24 | $23,156.32 | -$50,673.92 | -68.64% |
 Kevin Bresler TD Waterhouse Canada Inc. | 63 | $181 | $140.49 | -$40.51 | -22.38% |
Cellectar Biosciences, Inc. (CLRB) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cellectar Biosciences, Inc. ever had a stock split?
Cellectar Biosciences, Inc. Profile
| Biotechnology Industry | Healthcare Sector | James V. Caruso CEO | NASDAQ (CM) Exchange | 15117F880 CUSIP |
| US Country | 11 Employees | - Last Dividend | 16 Jun 2014 Last Split | 10 Nov 2005 IPO Date |
Overview
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company deeply engaged in the discovery, development, and intended commercialization of drugs for the treatment of cancer. The company harnesses its expertise in cancer biology to develop innovative treatments that aim to improve the outcomes for patients suffering from various types of cancer. Founded in 2002 and headquartered in Florham Park, New Jersey, Cellectar Biosciences adopts a focused approach towards targeting cancer cells, striving to minimize the impact on healthy tissues. Their research and development efforts are primarily centered around the use of phospholipid drug conjugates (PDCs) to create more effective and safer cancer therapies.
Products and Services
1. CLR 131 (iopofosine I-131)
This is the lead phospholipid drug conjugate (PDC) candidate of Cellectar Biosciences, currently undergoing various stages of clinical trials. CLR 131 is being studied in a Phase 2 clinical trial targeting patients with B-cell malignancies, which include various forms of lymphoma and leukemia. Additionally, the drug is involved in a Phase 2a clinical study focusing on patients with relapsed or refractory Waldenstrom's macroglobulinemia, multiple myeloma, and non-Hodgkin's lymphoma. For pediatric oncology, CLR 131 is under Phase 1 clinical trials aimed at treating children with relapsed or refractory solid tumors, lymphomas, and malignant brain tumors. Another Phase 1 study is investigating its effects on pediatric patients with head and neck cancer, marking the drug's potential versatility across different cancer types.
2. CLR 1900 Series
Currently in the preclinical development stage, CLR 1900 is a chemotherapeutic PDC program by Cellectar Biosciences aimed at treating solid tumors. This initiative represents the company’s efforts to broaden its portfolio by developing therapeutics designed to target cancer cells while sparing healthy cells, potentially reducing the adverse side effects associated with traditional chemotherapy.
In pursuit of advancing its drug development programs, Cellectar Biosciences has entered into strategic collaborations. Notably, the company collaborates with Orano Med to develop CLR 12120 Series, a partnership that exemplifies its commitment to leveraging external expertise and resources. Additionally, the collaboration with LegoChemBio underscores Cellectar Biosciences’ dedication to innovation and its strategy of partnering with specialised entities to enhance its R&D capabilities and expedite the development of its PDC platforms.
